JAMA Internal Medicine published the study.
Here are five points:
1. The study found industry payments to Massachusetts physicians correlated with higher brand-name drug prescriptions for high cholesterol.
2. A physician’s brand-name statin prescribing rate increased 0.1 percent for every $1,000 in industry payment.
3. Brand-name statins exceed generics cost by two to four times.
4. The researchers clarified many factors impact the brand-name prescribing rates, and they are not suggesting a causal relationship.
5. The study authors hope the results will push for reduced industry influence.
More articles on practice management:
How many PAs, NPs do medical practices typically employ? 5 statistics
Is a little patient mistrust always a bad thing? 4 thoughts
FDA panel supports mandatory opioid training for physicians — 5 findings from the FDA’s ER/LA REMS assessments
